SEC For	m 4																
	FORM	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549												OMB APPROVAL			
Section 16. Form 4 or Form 5 obligations may continue. See					NT OF CHANGES IN BENEFICIAL OWNERSHIP									OMB Number: 3235-0287 Estimated average burden hours per response: 0.5			
Instruc	tion 1(b).			Filed pu o	rsuant r Secti	to Section on 30(h) c	n 16(a of the	a) of the Secu Investment C	rities Exchan Company Act	ige Act of 1 of 1940	.934						
1. Name and Address of Reporting Person <sup>*</sup> Sistilli Carlo					2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Edesa Biotech, Inc.</u> [ EDSA ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) C/O EDESA BIOTECH INC.					3. Date of Earliest Transaction (Month/Day/Year) 02/28/2022							Officer (give title Other (specify below) below)					
100 SPY COURT				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) MARKHAM A6 L3R 5H6					X								·				
(City) (State) (Zip)																	
		Tab	ole I - Non-De	erivativ	ve Se	curities	s Ac	quired, Di	isposed c	of, or Be	neficial	ly Owned					
Date				ransactio e onth/Day/Y	'ear)	2A. Deemo Execution if any (Month/Da	Date	<ul> <li>Transaction Dispose</li> <li>Code (Instr. 5)</li> </ul>		ities Acquired (A) o d Of (D) (Instr. 3, 4 a		Beneficia Owned F	s Form Illy (D) of ollowing (I) (I		m: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership	
								Code V	Amount	(A) oi (D)	Price	Price Reported Transaction (Instr. 3 and				(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Yea	ate, Transactio Code (Inst				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amou of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Stock Option (right to buy)	\$3.71	02/28/2022		A		11,000		(1)	02/28/2032	Common Shares	11,000	\$0.00	11,000	D	D		

Explanation of Responses:

1. This option vests monthly in equal proportions over 12 months beginning on the Grant Date.

<u>/s/ Carlo Sistilli</u>

\*\* Signature of Reporting Person

<u>03/07/2022</u> Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.